IDiyas

For the Inventor, By the Inventor

West Roxbury, MA, United States of America

Derun Li

USPTO Granted Patents = 25 

 

Average Co-Inventor Count = 11.6

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Scotch Plains, NJ (US) (2016 - 2021)
  • Brighton, MA (US) (2019 - 2021)
  • West Roxbury, MA (US) (2020 - 2024)
  • Roxbury, MA (US) (2024)

Company Filing History:

goldMedal23 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal2 out of 2 
 
Nimbus Wadjet, Inc.
 patents
bronzeMedal1 out of 227 
 
Mochida Pharmaceutical Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...
Loading Chart...
25 patents (USPTO):
1. 12440496 - Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes (2025-10-14),
2. 12421233 - WRN inhibitors (2025-09-23),
3. 12344609 - WRN inhibitors (2025-07-01),
4. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),
5. 12275729 - Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-14),
6. 12240867 - Arginase inhibitors and methods of use (2025-03-04),
7. 12215116 - Arginase inhibitors and methods of use (2025-02-04),
8. 12065438 - Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors (2024-08-20),
9. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2024-07-09),
10. 11498904 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2022-11-15),
11. 11319283 - Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2022-05-03),
12. 11274111 - Arginase inhibitors and methods of use (2022-03-15),
13. 11208407 - Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-12-28),
14. 11111232 - Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-09-07),
15. 11034661 - Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors (2021-06-15),

Title: **Derun Li: Innovator in Arginase Inhibition**

Introduction

Derun Li is a prominent inventor based in West Roxbury, MA, with a remarkable portfolio of 20 patents. His work primarily focuses on developing innovative solutions in the field of pharmaceuticals, particularly concerning arginase inhibition, which holds potential in treating various diseases.

Latest Patents

Among his latest innovations are patents related to arginase inhibitors. These patents describe compounds of Formula (I) and their pharmaceutically acceptable salts, which function as arginase inhibitors. They aim to prevent, treat, or act as remedial agents for diseases associated with arginase, showcasing Derun's commitment to advancing medical science and improving patient outcomes.

Career Highlights

Derun Li has made significant contributions to the pharmaceutical industry through his work with renowned companies such as Merck Sharp & Dohme Corporation and Mochida Pharmaceutical Co., Ltd. His expertise in drug development and innovation has established him as a critical figure within the realm of pharmaceuticals.

Collaborations

Throughout his career, Derun has collaborated with several talented individuals, including Hongjun Zhang and Yongxin Han. These partnerships have fostered an environment of innovation, allowing for the successful development of various therapeutic agents aimed at combating arginase-related diseases.

Conclusion

Derun Li's dedication to innovation, evidenced by his extensive patent portfolio and impactful collaborations, underscores his pivotal role in the advancement of pharmaceutical solutions. His work continues to pave the way for new treatments, illustrating the power of innovation in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…